<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797923</url>
  </required_header>
  <id_info>
    <org_study_id>3-2020-0237</org_study_id>
    <nct_id>NCT04797923</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination</brief_title>
  <official_title>A Phase II Study Evaluating Efficacy and Safety of Conversion Surgery After Intraperitoneal Paclitaxel in Combination With Systemic Capecitabine and Oxaliplatin Chemotherapy in Advanced Gastric Cancer Patients With Peritoneal Dissemination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced gastric cancer combined with peritoneal seeind has dismal prognosis with poor&#xD;
      response to systemic chemotherapy and with rapid aggravation of symptoms such as abdominal&#xD;
      pain, ileus, and poor nutritional intake. Intraperitoneal (IP) chemotherapy through IP port&#xD;
      or catheter has lower complication than HIPEC (hyperthermic intraperitoneal chemotherapy) and&#xD;
      can deliver higher dose of chemotherapy with less systemic toxicity. IP chemotherapy combined&#xD;
      with systemic chemotehrapy showed benefit in several clinical trials, despite lack of&#xD;
      statistical significance in phase 3 clinical trial. Proper dose/combination of&#xD;
      chemotherapeutic agents and indication of IP chemotherapy should be investigated through&#xD;
      prospective, large-scale clinical trials.&#xD;
&#xD;
      Conversion surgery after cytotoxic chemotherapy showed improved survival in retrospective&#xD;
      studies. Our hypothesis is that IP chemotherapy combined with systemic chemotherpay&#xD;
      (capecitabine + oxaliplatin) would improve success rate of conversion surgery with R0&#xD;
      resection. In the present study, the treatment regimen consists of intraperitoneal paclitaxel&#xD;
      combined with oxaliplatin and capecitabine (XELOX), and will be performed following surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of R0 resection</measure>
    <time_frame>30 days after the surgery</time_frame>
    <description>Success rate of conversion surgery (Rate of R0 resection)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Intraperitoneal paclitaxel with systemic chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1. Treatment: IP chemotherapy + Systemic chemotherapy</intervention_name>
    <description>1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks</description>
    <arm_group_label>Intraperitoneal paclitaxel with systemic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>2. Response evaluation after 4 cycles of IP + systemic chemotherapy</intervention_name>
    <description>2. Response evaluation after 4 cycles of IP + systemic chemotherapy&#xD;
Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.&#xD;
If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.&#xD;
IP chemotherapy should not exceed total of 8 cycles.</description>
    <arm_group_label>Intraperitoneal paclitaxel with systemic chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed advanced gastric cancer adenocarcinoma&#xD;
&#xD;
          2. Peritoneal metastasis histopathologically confirmed by laparoscopy or laparotomy and&#xD;
             PCI &lt;12 (including patients with no gross peritoneal lesion and cytology positive)&#xD;
&#xD;
          3. No prior surgery for curative aim and previous chemotherapy for recurrent/metastatic&#xD;
             gastric cancer&#xD;
&#xD;
          4. Patient who is willing and able to provide written informed consent/assent for the&#xD;
             trial&#xD;
&#xD;
          5. Age between 19 and 75 years&#xD;
&#xD;
          6. Measurable lesion according to RECIST 1.1 criteria&#xD;
&#xD;
          7. ECOG performance status 0-1&#xD;
&#xD;
          8. Have adequate organ function&#xD;
&#xD;
               -  ANC ≥ 2,000/uL,&#xD;
&#xD;
               -  hemoglobin ≥ 9.0g/dL&#xD;
&#xD;
               -  platelet ≥ 100,000/uL&#xD;
&#xD;
               -  total Bilirubin: ≤ 1.5 × upper normal limit&#xD;
&#xD;
               -  Creatinine ≤ 1.5 × upper normal limit or Creatinine clearance ≥ 60ml/min&#xD;
&#xD;
               -  AST/ALT ≤ 3.0 x upper normal limit&#xD;
&#xD;
               -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
               -  PT or INR, aPTT ≤ 1.5 × upper normal limit&#xD;
&#xD;
          9. Should agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous systemic chemotherapy for metastatic/recurrent advanced gastric cancer&#xD;
&#xD;
          2. Patient who has distant metastasis or para-aortic lymph node metastasis or&#xD;
             retroperitoneal metastasis except peritoneal metastasis. (But the patient who has&#xD;
             ovarian metastasis with resectable status can be enrolled.)&#xD;
&#xD;
          3. Primary tumor cannot be resected because of direct invasion to other important organ.&#xD;
             (But, if the invaded organ can be resected together, such as spleen, gallbladder,&#xD;
             distal pancreas, and liver, the patient can be enrolled)&#xD;
&#xD;
          4. BMI ≤ 18.5 kg/m2&#xD;
&#xD;
          5. HER2 positive patient (IHC 3+, 2+ with in situ hybridization +)&#xD;
&#xD;
          6. Remnant gastric cancer&#xD;
&#xD;
          7. Intolerable to oral intake of chemotherapeutic agent or have malabsorption syndrome&#xD;
&#xD;
          8. Known additional malignancy that is progressing or requires active treatment in recent&#xD;
             3 years (excluding skin basal cell carcinoma, skin squamous cell carcinoma, thyroid&#xD;
             cancer, or in situ cervix cancer that has undergone potentially curative therapy)&#xD;
&#xD;
          9. Symtomatic CNS metastasis and/or leptomeningeal seeding&#xD;
&#xD;
         10. Autoimmune disease in recent 2 years requiring systemic therapy&#xD;
&#xD;
         11. Clinically significant heart disease&#xD;
&#xD;
         12. Peripheral neuropathy ≥ Grade 2&#xD;
&#xD;
         13. Pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment&#xD;
&#xD;
         14. History of HIV, HBV, or HCV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seung Ho Choi, M.D., Ph.D.</last_name>
    <phone>82-2-2019-3374</phone>
    <email>choish@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangnam Severacne Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangnnam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Ho Choi</last_name>
      <phone>82-2-2019-3374</phone>
      <email>choish@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Seung Ho Choi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Intraperitoneal chemotherapy, Conversion surgery, Advanced gastric cancer, peritoneal carcinomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

